New crop of data suggests drug can speed recovery from COVID-19

Move comes after drug showed preliminary efficacy in clinical trial in late April

California’s Gilead Sciences has outlined a plan to ramp up production of newly USA-approved COVID-19…

As had been widely expected, Gilead Sciences on Thursday announced that the Japanese Ministry of Health,…

Gilead Sciences scored a massive win earlier this week with its first positive data readout for investigational candidate remdesivir in treating patients with severe COVID-19. Gilead already has its own supply of the drug humming in anticipation of high demand, but opportunities are out there for a partner to join in. 

Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization.

While Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at up to $4,460 per patient. That means it could easily rake in blockbuster sales this year, at least theoretically.

Gilead made waves on Friday with its emergency FDA approval for remdesivir quickly on the heels of a controlled trial data release. But while it’s an important first step, other COVID-19 medicines will likely be coming down the line, analysts wrote.

The world is waiting for Gilead Sciences to set a price tag for remdesivir, the first brand-new med authorized to treat COVID-19. Its choice will affect Gilead's reputation and bottom line, set a tone for follow-up meds—and either help polish up the pharma industry's image or create a new flashpoint for criticism.

Gilead Sciences' remdesivir, now called Veklury, has won a fast Japanese nod in SARS-CoV-2. The Big Biotech's scouting licensing partners to ramp up supply around the world. Eli Lilly has signed on China's Junshi Biosciences to develop neutralizing antibodies against the novel coronavirus. And more.

When Gilead Sciences scored a groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the U.S. government. But the federal rollout has gotten off to a rocky start. 

The FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir for the treatment of COVID-19 in adults and children hospitalized with severe disease.

The European Medicines Agency has begun a rolling review of data on Gilead’s remdesivir, positioning it to cut the time it takes to decide whether to approve the drug in COVID-19 patients.

The drug helped some coronavirus patients recover faster. But it's hardly everything we'd wished for.

Since the drug was granted emergency use authorization, doctors have been left with no clear path to get it.

Ronny Gal of Sanford C. Bernstein says he thinks remdesivir will not be the most significant revenue contributor for Gilead Sciences over time. He also explains his rationale for raising the company's price target to $75 from $72.

"This drug makes a big difference, especially if you were worried about a second wave of infections after we reopened the economy," the "Mad Money" host said.

Dr. Scott Gottlieb, Former FDA Commissioner, joins "Closing Bell" to discuss the coronavirus pandemic.

The US food and drug regulatory body has allowed the emergency use of an investigational anti-viral vaccine to treat COVID-19 patients after some researches, including one led by an Indian-American physician, found that the drug helped recover some of the infected cases faster.

The Food and Drug Administration (FDA) gave emergency use authorisation (EUA) for the use of investigational anti-viral Remdesivir for the treatment of COVID-19 patients. "I'm pleased to announce that Gilead now has an EUA from the FDA for Remdesivir," US President Donald Trump told reporters at the White House on Friday.

Remdesivir is given to patients through a vein one time each day for up to 10 days depending on recommendations of healthcare providers. The US National Institute of Allergy and Infectious Diseases (NIAID) announced the results of a trial involving more than 1,000 people on Wednesday.

It found that hospitalised COVID-19 patients with respiratory distress got better quicker than those on a placebo. Specifically, patients on the drug had a 31 percent faster time to recovery. "Although the results were clearly positive from a statistically significant standpoint, they were modest," Anthony Fauci, the scientist who leads the NIAID, said. While not considered a miracle cure, Remdesivir's trial achieved a "proof of concept," according to Fauci that could pave the way for better treatments.

Possible side effects of Remdesivir include infusion-related reactions and increases in levels of liver enzymes. "These are not all the possible side effects of Remdesivir. It is still being studied so it is possible that all of the risks are not known at this time," said the FDA.

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Remdesivir is highly effective in stopping the replication of coronavirus, according to new research published in the iJournal of Biological Chemistry/i by scientists at the University of Alberta.

The US Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) for the experimental remdesivir (anti-viral medication) to treat COVID-19 patients.

Most seriously ill COVID-19 patients will be treated with the antiviral medication Remdesivir in America the maker of the drug has announced, as tensions

Exclusive: Disappointing results revealed in draft documents published accidentally by WHO

US-run trial of Gilead coronavirus therapy demonstrates ‘significant positive effect’

Gilead’s potential coronavirus treatment stirs investor hopes but evidence on effectiveness is mixed

Biotech group’s shares have soared this year on hopes drug could be used to treat coronavirus

US-led trial shows positive results in hastening recovery time for coronavirus patients

Gilead Sciences announced Wednesday that more than half of the 397 severely ill coronavirus patients it treated with the antiviral Ebola drug Remdesivir were discharged from hospitals.

In an interview with Good Morning America on Thursday, Dr. Aneesh Mehta of Emory University Medical School - one of the institutions which took part in the study - spoke of its success.

The FDA may announce its decision allowing emergency use authorization of an antiviral remdesivir for coronavirus patients as early as Wednesday.

Remdesivir, an antiviral made by California-based Gilead Sciences, was shown to slash recovery times in a global trial of more than 1,000 patients, including Britons.

Gilead Sciences CEO Daniel O'Day wrote in an open letter obtained by Fox News that early results on his company's drug remdesivir's benefits for coronavirus patients offer 'hope' that's badly needed.

Gilead Sciences said Thursday in an earnings report that it is ramping up production of its antiviral remdesivir, and could make 'several million' 10-day treatment courses of the drug for 2021.

Gilead Sciences CEO Daniel O'Day told Stat News that his company understands its responsibility to make its antiviral drug affordable after it showed promise for treating coronavirus.

President Donald Trump announced Friday that the FDA has approved the drug remdesivir for emergency use in hospitalized coronavirus patients. 

Gilead Scienced, based in California, said it's in talks with 'several' generic drug makers across Europe and Asia, including India and Pakistan, to produce its experimental coronavirus drug remdesivir.

A report from a cost watchdog estimated that it costs $9.32 to manufacture one 10-day course of remdesivir treatment and that, if proven to save live, it could cost $4,500 per treatment.

अमेरिकी कंपनी गिलियड साइंसेज (Gilead Sciences) का दावा है कि कोरोना वायरस (COVID-19) के इलाज में Remdesivir एक कारगर दवाई साबित होगी. इस पर प्रयोग जारी हैं. आइए जानते हैं इस दवाई से जुड़ी खास जरूरी बातें.

नैटको फार्मा लिमिटेड (Natco Pharma Ltd) और लॉरस लैब्स लिमिटेड (Laurus Labs Ltd) एंटी वायर ड्रग रेमेडिसविर (Remdesivir) बनाने के लाइसेंस के लिए अमेरिकी फार्मास्युटिकल कंपनी गिलियड साइंस इंक (Gilead Sciences Inc) से बातचीत की है.

Remdesivir is authorised for the treatment of hospitalised patients with severe Covid-19 disease though the optimal duration of treatment is still being studied in ongoing clinical trials.

Remdesivir is an investigational antiviral drug that may be found effective against the virus that causes Covid-19

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, will start production this month of the experimental antiviral drug remdesivir, which has shown promise in fighting the new coronavirus, a senior company executive said on Tuesday.

Recent clinical trial results and the decision by the US Food and Drug Administration to issue 'Emergency Use Authorisation' for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally, Gilead said.

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

Checks with industry on when can production begin here for trials

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts